Major medical journal reports breakthrough treatment results for aggressive form of gastroesophageal cancer.
A new cancer treatment has shown significant promise in treating an aggressive form of stomach and oesophageal cancer, according to results published in a leading medical journal.
The New England Journal of Medicine announced the findings from a major clinical trial testing zanidatamab, a new drug designed to target HER2-positive gastroesophageal adenocarcinoma. This particular type of cancer affects the stomach and lower oesophagus.
The Trial Results
The phase 3 HERIZON-GEA-01 trial compared the new treatment against the current standard therapy. Patients receiving zanidatamab combined with chemotherapy lived longer without their cancer progressing compared to those on the existing treatment.
Current treatment typically involves trastuzumab plus chemotherapy. But the trial showed zanidatamab performed better both on its own with chemotherapy and when combined with another drug called tislelizumab.
HER2-positive cancers make up roughly 20 per cent of gastroesophageal adenocarcinomas. These cancers produce too much of a protein called HER2, which helps cancer cells grow and spread.
What The Numbers Show
Progression-free survival measures how long patients live without their cancer getting worse. The trial found this period was extended for those on the new treatment regime.
The research represents years of work testing the drug combination in hospitals across multiple countries. Phase 3 trials are the final stage before regulators decide whether to approve new treatments for widespread use.
Gastroesophageal adenocarcinoma remains one of the more challenging cancers to treat. It often spreads quickly and can be difficult to detect in early stages.
The Road Ahead
The results will now be reviewed by medicines regulators including the UK’s Medicines and Healthcare products Regulatory Agency. This process typically takes several months.
Cancer specialists will examine the full trial data to understand which patients might benefit most from the new approach. They’ll also assess potential side effects and how the treatment fits with existing care pathways.
Source: @NEJM
Key Takeaways
- New drug zanidatamab shows better results than current standard treatment for HER2-positive gastroesophageal cancer
- Phase 3 trial results published in prestigious New England Journal of Medicine
- Treatment targets aggressive form of stomach and oesophageal cancer affecting around 20% of cases
What This Means for Kent Residents
Kent cancer patients and their families should discuss these developments with their oncology teams at local hospitals including Maidstone and Tunbridge Wells NHS Trust and East Kent Hospitals. While the treatment isn’t yet available on the NHS, the results offer hope for future treatment options. Anyone with concerns about stomach or oesophageal symptoms should contact their GP or call NHS 111 for advice.
New Cancer Drug Shows Promise for Stomach Cancer Patients Quiz
5 questions